• Whitehawk Therapeutics entered a global collaboration with Biocytogen to develop bispecific antibody-drug conjugates for oncology.
• Biocytogen will supply up to five fully human bispecific antibodies from its RenLite platform for evaluation with Whitehawk’s ADC linker-payload technologies.
• Whitehawk holds an option to advance resulting BsADC candidates, taking global rights and full program control if exercised.
• Biocytogen will receive an upfront payment, milestones tied to development, regulatory and commercial events, and low single-digit royalties on net sales.
• Whitehawk targets new ADC IND filings within 12-24 months, using the collaboration to expand its pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.